Search PubMed⌕ Search

Biomedical subjects

S K Singhal

Publications and source records attributed to S K Singhal.

At least 37 records · Page 2Linked to original sources
PubMed1989

Identification of a human bone marrow-derived immunoenhancing factor, BDEF.

In this report we describe the production and biological activity of human bone marrow-derived enhancing factor (BDEF). This factor is the constitutive product of cultured human BMC and could initially be recovered by ultrafiltration of cell-free BM supernatants to yield a crude fraction of Mr greater than 10,000 Da. This preparation can enhance the Ab response of human tonsillar cells, as well as murine spleen cells, to SRBC. HPLC fractionation of BM supernatants enriches for enhancing activity in a peak with an approximate Mr of 60 kDa. PAGE gel analysis reveals two protein bands which migrate to this area, one of 60 kDa, and a slightly smaller protein at 55 kDa. Antibodies generated against the above two proteins were shown to be specific by Western blotting and could recognize the native BM proteins as determined by ELISA. The antibodies were used to affinity purify the respective proteins, p60 and p55. The BM protein p60, but not p55, was able to enhance Ab synthesis in vitro and was also mitogenic for murine BMC and thymocytes. The addition of anti-p60 Ab to human tonsillar cells cultured with SRBC and human BDEF preparations resulted in abrogation of enhancement. These findings support the notion that the BM protein p60 is BDEF and that it may represent a novel enhancing molecule produced by normal human BM.

Adjuvants, Immunologic↗
PubMed1989

Regulation of autoimmunity in normal and rheumatoid individuals by bone marrow-derived natural suppressor cells and their suppressor factor: BDSF.

Natural suppressor activity is defined as the ability of unstimulated effector cells to suppress responses of lymphoid cells to antigenic and mitogenic stimuli in an MHC unrestricted manner. We have described natural suppressor cells in bone marrow exerting such a function through a suppressor factor termed BDSF. In this report we demonstrate the ability of BDSF to regulate the in vitro EBV- and PWM-induced production of both IgM and IgM rheumatoid factor antibodies of lymphoid cells obtained from normal individuals and those with rheumatoid arthritis. BDSF therefore may play a role in the normal BM microenvironment suppressing primary IgM antibody responses. Since autoantibody responses are similarly suppressed, functional alteration or lack of BDSF may be responsible for the emergence of autoantibody-producing cells in bone marrow during certain autoimmune states.

Arthritis, Rheumatoid↗
PubMed1989

Role of d-tubocurarine in suppression of cardiovascular responses following endotracheal intubation.

The role of d-tubocurarine in blocking the hypertensive tachycardiac response following laryngoscopy and endotracheal intubation was evaluated in 45 female patients aged 20-40 yr. The patients belonging to grade I (of American Society of Anaesthesiologists) and undergoing elective surgical procedures under general anaesthesia were allocated in 3 equal groups. Patients in the 3 groups received 1.5 mg/kg succinylcholine, 0.6 mg/kg d-tubocurarine and 0.12 mg/kg pancuronium bromide, respectively for intubation. There were no dysrhythmias in any of the groups following endotracheal intubation. There was significant (P less than 0.01) fall in blood pressure following induction prior to intubation in all the three groups. Maximum fall was noted in group II (23.53 +/- 7.21 mmHg in mean arterial pressure). Following endotracheal intubation, blood pressure and heart rate increased significantly (P less than 0.01) in all 3 groups. Maximum increase was observed in group I (26.4 +/- 4.95 mmHg in mean arterial pressure and 19.07 +/- 6.54 beats/min in heart rate). Blood pressure and heart rate increases in groups II and III were comparable. Our findings indicate that hypotension produced by d-tubocurarine through ganglion blockade is not effective in attenuating the cardiovascular responses following endotracheal intubation. It is also possible that increased cardiovascular response following endotracheal intubation may not be due to sympathetic ganglion stimulation.

Adult↗
PubMed1988

Production of human bone marrow-derived suppressor factor. Effect on antibody synthesis and lectin-activated cell proliferation.

Natural suppressor cells resident in normal human bone marrow (BM) exert potent suppressor activity on in vitro antibody responses and other immune functions. A suppressor-enriched population of BM cells can constitutively produce a soluble mediator with similar suppressor activity and kinetics as the suppressor cells. This novel BM-derived suppressor factor (BDSF) suppresses human in vitro primary antibody responses as well as lectin-activated proliferative responses. The mediator (BDSF) has a Mr of less than 1.5 kDa, contains a lipid component, and is insensitive to indomethacin treatment. The BM cells producing the factor bear the HNK-1 surface marker but not T, B, or macrophage markers. The ability of BDSF to suppress Ag-dependent IgM responses during the inductive phase makes it an ideal molecule with the potential to regulate early immune and hemopoietic events within the BM compartment.

Antibodies, Monoclonal↗
PubMed1988

Suicide with dapsone.

A case of suicide with dapsone is reported in a female medico chemical analysis report confirmed it to be death due to dapsone. Management in case of dapsone poisoning is also discussed.

Dapsone↗
PubMed1986

Immunoregulatory activity of human bone marrow. Identification of suppressor cells possessing OKM1, SSEA-1, and HNK-1 antigens.

Human bone marrow contains natural regulatory cells capable of suppressing the in vitro primary IgM response of normal tonsillar cells. The suppression is mediated by non-T cells possessing Fc receptors, OKM1, SSEA-1, and HNK-1 antigens on their surface. The suppression was abrogated by treatment of bone marrow cells (BMC) with anti-HNK-1 or anti-SSEA-1 antisera and complement. Furthermore, BMC depleted of HNK-1+ cells could respond in a primary in vitro antibody response when provided with accessory T cells and macrophages from tonsillar cells. Our findings support the idea that HNK-1+ and HNK-1- BMC populations act antagonistically in the regulation of antibody synthesis. Further, the finding of HNK-1+, SSEA-1+, and OKM1+ suppressor cells in human bone marrow may represent a precursor phenotype of mature natural killer cells with potent immunoregulatory activity.

Antigens, Surface↗
PubMed1986

The immunoregulatory role of bone marrow. IV. Role of an immunoenhancing glycoprotein derived from murine bone marrow.

Bone marrow-enhancing factor (B-EF) is the spontaneous product of whole bone marrow cells cultured in serum-free medium for a short term (24-48 hr). The factor is prepared by ultrafiltration of BMC supernates to yield a preparation with a MW of greater than 10,000. Production of the factor is not dependent upon antigenic or mitogenic stimulation of BMC, but is inhibited by treatment of BMC with cycloheximide. B-EF augments the in vitro primary PFC response to SRBC, as well as in vitro secondary IgM and IgG PFC responses to SRBC. Enhancement by B-EF is antigen dependent, genetically nonrestricted, and maximal when present at the initiation of culture. B-EF cannot induce a polyclonal antibody response like the polyclonal activator LPS. B-EF is directly mitogenic for thymocytes, bone marrow, and whole spleen cells, but fails to act as a costimulator of thymocyte proliferation in the presence of Con A. B-EF cannot support the growth of the IL-2-dependent cell line CTLL-2. Since B-EF has not been purified, the supernatant may contain more than one activity. The factor is heat labile at 65 degrees C and is sensitive to enzymatic digestion with trypsin and neuraminidase; this implies that B-EF may be a glycoprotein.

Adjuvants, Immunologic↗
PubMed1986

Regulation of lymphoid colony growth by factors derived from human bone marrow.

We have previously demonstrated the ability of soluble factors derived from cultured murine and human bone marrow supernatants to modulate a variety of lymphoid functions, including DNA synthesis. In the present report, we show that human marrow supernatants contain a suppressor factor (BSF) that suppresses T-lymphoid colony formation, and an augmenting factor (BEF) that enhances T-colony growth. BSF suppression exhibits no tissue specificity, affecting marrow-derived and peripheral T colonies similarly. The suppressive activity occurs prior to mitogenic activation by TCGF. In contrast, a preferential augmentation of the size and number of marrow-derived T-cell colonies, as compared to peripheral T-cell colonies, was observed in the presence of BEF. BEF required prior mitogen activation of the colony inocula to effect colony enhancement. In addition, the response to BEF was greater for E- than for E+ colony-forming cells, indicating the target of BEF activity to be an early T cell. The active subfraction of BEF with colony-enhancing activity was found to be between 8000 and 30,000 daltons.

Animals↗
PubMed1985

IgM rheumatoid factor autoantibody and immunoglobulin-producing precursor cells in the bone marrow of humans.

The natures of the IgM rheumatoid factor (RF)-, IgM-, and IgG-secreting cells in the human bone marrow as compared to the peripheral blood, have been investigated by (1) response to the polyclonal B-cell activator, the Epstein-Barr virus (EBV), (2) sensitivity to the S-phase specific antimetabolite hydroxyurea, (3) presence of the BA-1 and Ia antigens on the cell surface, and (4) cell size, as determined by counter flow elutriation. The EBV-inducible bone marrow IgM-RF precursors derived from medium to large B cells that were inhibited by hydroxyurea pretreatment. The marrow total IgM response derived from small to medium size cells, and was only partially inhibited by hydroxyurea. Hydroxyurea had no effect on IgM-RF or IgM synthesis by peripheral blood cells. These results indicate that the marrow EBV-induced IgM-RF response is not representative of the response by peripheral blood cells, moreover; the marrow RF secreting response arises from a dividing cell pool that may represent newly generated autoreactive B cells.

Aging↗
PubMed1985

Regulation of an in vitro anti-DNA antibody response by thymocytes and T cells from NZB/W and normal mice.

The spontaneous in vitro anti-DNA antibody response generated by preautoimmune and many normal mouse spleen cells was suppressed by the addition of syngeneic thymocytes or splenic T cells. Suppressive activity was found in normal mice (DBA/2J) and to an equivalent degree in the autoimmune (New Zealand Black X New Zealand White)F1 (B/W) strain. The suppressor cells were cortisone-resistant, radiosensitive and carried Lyt 1 and Lyt 2 markers. Nonspecific suppression was not involved since the primary and primed in vitro anti-sheep erythrocyte (anti-SRBC) responses were unaffected. Both spontaneous and lipopolysaccharide-stimulated anti-DNA antibody responses could be suppressed. There was no difference in the suppressive activity of cells from young or old, normal or autoimmune mice. These T cells may therefore play a role in preventing the anti-DNA antibody response in normal and young B/W mice, but evidently fail to influence the development of in vivo anti-DNA autoimmune responses in the old B/W mice.

Aging↗
PubMed1985

A naturally occurring polyclonal B cell activator of normal and autoantibody responses.

Previous studies from this laboratory have demonstrated the presence of a suppressor molecule in B/W spleen cultures. Now we present evidence suggesting the existence of a polyclonal B cell activator (sPBA) spontaneously released by B/W splenocytes. Large sPBA (120,000 to 160,000 daltons) was separable from splenic inhibitory factor(s) (less than 10,000 daltons) by ultrafiltration. Reconstitution experiments demonstrated these two molecules had antagonistic effects on splenocyte mitotic events. sPBA is directly mitogenic for T cell-depleted, B cell-enriched cultures. Furthermore, sPBA augments antibody responses in the presence of antigen, or stimulates antibody responses in the absence of antigen. sPBA appears to stimulate IgG as well as IgM antibody production. sPBA stimulates significant in vivo anti-ssDNA responses in preautoimmune B/W but not DBA mice. Physiochemical studies suggest sPBA is a DNA protein complex. sPBA activity is completely lost by heating to 56 degrees C for 30 min. sPBA activity is precipitated at pH 7.8 to 8.0. Furthermore, sPBA preparations do not display significant endotoxin levels or IL 1 and IL 2 activity.

Adsorption↗
PubMed1983

A novel cell surface antigen (T305) found in increased frequency on acute leukemia cells and in autoimmune disease states.

Monoclonal antibody T305, prepared by immunizing mice with the T-ALL derived cell line RPMI-8402, immunoprecipitates a single chain glycoprotein with m.w. 160,000 daltons (under reducing conditions) or 180,000 daltons (under nonreducing conditions). In immunofluorescence assays, antibody T305 reacted with a subpopulation of T cells in normal blood (22 +/- 6%), thymus (28 +/- 11%), and lymph node (24 +/- 6%). Increased frequency of T cells reactive with antibody T305 was found in peripheral blood of patients with infectious mononucleosis (greater than 80%), graft-vs-host disease after bone marrow transplantation (65 +/- 11%), acquired immunodeficiency syndrome (53 +/- 12%). The T cells in synovial fluid of patients with rheumatoid arthritis had increased frequency of antibody T305 reactive cells (59 +/- 8%) as compared to their peripheral blood (18 +/- 7%). Two color immunofluorescent studies demonstrated that the T305+ T cells predominantly co-stained with antibody Leu 2a (suppressor/cytotoxic subset) in both normals and disease state blood. After cell sorting to obtain T305+ and T305- subpopulations, we demonstrated that a) natural killer and antibody-dependent cellular cytotoxicity activity in normal blood was in the T305+ but not T305- T cells; b) cytotoxic T cells induced by mixed lymphocyte reaction were predominantly T305+; c) T305- T cells could be induced in vitro to express T305 antigen by mitogens or allogeneic B cells; d) the DNA content of T305+ and T305- T cells in normal blood was similar (greater 95% of cells with G0/G1 level); e) after mitogen stimulation, T305 antigen induction on previously T305- cells occurs before S-phase; and f) significantly more [3H]-thymidine after mitogen stimulation was incorporated by originally T305- cells than by originally T305+ cells (p less than 0.001). The T305 antigen was not restricted to T cells because it was also found on myeloid precursors in bone marrow but was not present on polymorphonuclear leukocytes, red blood cells, platelets, muscle, liver, skin, kidney, lung, or brain. Antibody T305 was found on 24/25 cases of acute leukemia (6 T-ALL, 10/11 cALL, 7 AML, and 1 AMOL) but not on 18 cases of chronic leukemia (B-CLL, T-CLL, null CLL, CML). The importance of the T305 antigen is that it is present on a high number of T cells in certain autoimmune diseases and on virtually all acute leukemia cells. Its distribution on immature and in vitro activated cells suggests that it may represent a receptor for signals related to cellular replication or differentiation.

Animals↗
PubMed1982

The immunoregulatory role of bone marrow. III. Further characterization of the suppressor cell and its mode of action.

In vitro primary antibody responses of spleen cells can be suppressed in a dose-dependent manner by the addition of bond marrow cells (BMC). This suppression was not abrogated by treatment of BMC with anti-Thy 1, anti-Lyt nor with anti-I-J antisera and complement. Furthermore, preculture of BMC with the synthetic thymic pentapeptide (TP5) or Soluble Thymic Factor (STF) before anti-Thy-1 treatment was similarly ineffective in removing the suppressor cell activity. Similarly, treatment of BMC with polyvalent anti-immunoglobulin serum or anti-Ia antiserum and complement failed to remove the suppressor activity. However, preparations of anti-H-2 and anti-stem-cell antisera were capable of significantly decreasing the suppressive ability of BMC. BMC were also shown to be capable of suppressing antibody responses induced by the polyclonal activators dextran sulphate (DxS), lipopolysaccharide (LPS) and purified protein derivative from tubercle bacilli (PPD). The non-specificity of this suppressor coupled with the absence of well-defined antigen on its surface may suggest that this cell represents a basic level of immune regulation.

Animals↗